PIM1 and neuroblastoma: They described PIM inhibition-resistant neuroblastoma cell lines, based on the high median lethal dose (LD50), and utilized a genome-wide CRISPR-Cas9 genetic screen to explore the mechanism of PIM inhibitor resistance.